There is an “innovative” new treatment option for Benign Prostatic Hyperplasia.
Benign Prostatic Hyperplasia is one of the most common diseases among men; and it is increasingly likely as men get older.
It translates into an increase in the volume of the prostate. It is a non-cancerous enlargement of the prostate, a gland located below the bladder and in front of the rectum, responsible for producing part of the seminal fluid.
This disease can compress the urethra, the channel through which urine is expelled, causing a series of uncomfortable urinary symptoms.
The most common symptoms are: difficulty initiating urination, weak or interrupted urinary flow, the need to urinate frequently, especially at night, the sensation of not emptying the bladder completely and urinary urgency.
It is not carcinogenic and does not increase the risk of prostate cancer, but it can affect quality of life due to uncomfortable urinary symptoms.
“Revolution”
Now the Institute for Focal Prostate Therapy is presenting the new treatment, iTind.
It is a medical device that is implanted transurethrally. It stays in the prostatic urethra for 5 to 7 days to dilate it, reads a statement sent to ZAP.
The placement and removal of the iTind are simple procedures, performed on an outpatient basis with sedation or local anesthesia.
It is a “revolution” in the treatment of these patients, describes José Sanches Magalhães, urologist and founder of the Institute of Focal Prostate Therapy.
The main aim of iTind is to provide immediate relief from the obstructive urinary symptoms associated with the disease, without causing adverse effects on sexual function.
iTind promises to be an “effective and minimally invasive alternative. This solution allows rapid relief of obstructive urinary symptoms without compromising sexual function, ideal for those who wish to avoid continuous medication or the risks of surgery.”
One of the advantages of this option is the low rate of need for salvage treatment in the first four years after the procedure, estimated at around 11%.
The iTind is suitable for patients with prostates between 20 and 60 ml in size, including those without a middle lobe or a small middle lobe. And it's ideal for those who don't want oral medication and for those who prefer to avoid surgical intervention.
